This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum ...

This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial ...

Lawyers warn that control over who administers Botox, especially those without medical education, is weak, and Botox imports are often untraceable.

AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a ...

Spanish scientists have produced a report on the growth of Clostridium botulinum and the risk of botulism following an ...

A quarter of over 130 people treated in public hospitals last year for suspected "space oil" consumption were under 18, the ...

Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted its patent application for its DMT410 program for the treatment ...

Application error: a client-side exception has occurred (see the browser console for more information).

DALLAS, TX / ACCESS Newswire / February 24, 2025 / Injectco - an injection-focused medical spa with multiple locations throughout the Metroplex - is thrilled to announce the opening of a newDallas ...

A set of twins took part in a study in 2006 tracking the differences when one used botox and the other didn't.

Leading figures from the world of medical aesthetics will be amongst the speakers when The Scottish Aesthetic Conference 2025 takes place in ...

A reliable method to treat post-amputation pain remains elusive, but a new Northwestern Medicine study conducted in ...